Streetbeat News

Equity Actions

FFIV

Analysts have provided mixed reviews on F5 (NASDAQ:FFIV) over the last three months, with 6 different ratings ranging from bullish to bearish. The average 12-month price target is $174.67, down from $176.50, with a high of $204.00 and a low of $160.00. Key analysts from firms like Keybanc, B of A Securities, and RBC Capital have adjusted their ratings and price targets, reflecting their views on the company's market dynamics and performance. F5 is a leader in application delivery controllers, with a focus on security, performance, and automation, and has shown positive revenue growth and strong financial health indicators such as net margin and ROE.

Portfolio Pulse from Benzinga Insights

January 18, 2024 | 1:00 pm

NVTA

Invitae Corporation (NYSE:NVTA) has seen a 6.1% increase in short interest since its last report, with 62.98 million shares sold short, representing 24.35% of its float. It would take about 6.01 days to cover all short positions. While an increase in short interest can indicate bearish sentiment, it doesn't necessarily predict a near-term price drop. Invitae's short interest is significantly higher than its peer group average of 5.44%.

Portfolio Pulse from Benzinga Insights

January 18, 2024 | 1:00 pm

WFC

Wells Fargo (NYSE:WFC) has received mixed analyst ratings over the past three months, with 11 analysts offering a range of bullish to indifferent perspectives. The average 12-month price target for WFC has increased to $53.72, up from $50.57, with a high estimate of $66.00 and a low of $47.00. Analysts have adjusted their ratings and price targets, reflecting their latest views on the company's performance. Wells Fargo, a major U.S. bank with $1.9 trillion in assets, faces challenges in revenue growth, net margin, ROE, ROA, and debt management, which may impact its stock performance.

Portfolio Pulse from Benzinga Insights

January 18, 2024 | 1:00 pm

META

NVDA

David Keller, CMT, Chief Market Strategist at StockCharts.com, discusses four potential scenarios for the S&P 500's performance over the next six to eight weeks. He emphasizes the importance of probabilistic analysis, considering alternative scenarios, and preparing to adapt portfolios accordingly. The scenarios range from very bullish, with the S&P 500 breaking to new all-time highs, to super bearish, with a retest of the October 2022 low around 4100. Key levels to watch are 4700-4800 for short-term range, with 4600 and 4450 as critical support levels. Keller also mentions that Meta Platforms, Inc. (META) and NVIDIA Corp. (NVDA) are leading growth names making new all-time highs.

Portfolio Pulse from David Keller

January 18, 2024 | 12:56 pm

PCSA

Processa Pharmaceuticals announced a 1-for-20 reverse stock split, with trading on a split-adjusted basis starting January 22, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 12:48 pm

CGC

Canopy Growth has upsized its private placement to $35 million, offering 8,158,510 units at a price of $4.29 each. This capital raise could indicate the company's need for additional funds to finance its operations or growth initiatives. Investors may view this as a positive sign of expansion or as a potential dilution of existing shares.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 12:31 pm

JBI

Janus International Group announced the completion of Clearlake Capital Group's exit from its investment in the company. This marks the end of Clearlake's involvement with Janus, which could have implications for the company's future strategy and financial structure.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 12:27 pm

CATX

Perspective Therapeutics, Inc. (NYSE:CATX) has announced the pricing of a public offering and private placement totaling approximately $80.8 million. The public offering is priced at $0.37 per share for 132,075,218 shares, and pre-funded warrants are priced at $0.369 for 30,086,944 shares. The company also granted underwriters a 30-day option to purchase up to an additional 24,324,324 shares at the public offering price, less discounts and commissions.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 12:04 pm

BBIO

BridgeBio Pharma has secured strategic financing from Blue Owl Capital and Canada Pension Plan Investment Board, with the potential to receive up to $1.25 billion. This capital infusion is aimed at supporting BridgeBio's mission to develop life-saving medicines for genetic diseases and cancers with clear genetic drivers. The financing includes an initial $350 million investment and the possibility of an additional $900 million based on the achievement of certain milestones.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 12:01 pm

ADBE

Adobe (NASDAQ:ADBE) received mixed analyst ratings with 13 analysts offering their perspectives in the past three months. The average 12-month price target for Adobe is $654.54, marking a 5.21% increase from the previous target of $622.14. Analysts from firms like Exane BNP Paribas, Piper Sandler, Barclays, RBC Capital, Stifel, Citigroup, BMO Capital, KGI Securities, Oppenheimer, and DA Davidson have provided various ratings and adjusted their price targets. Adobe's financial performance shows a market cap above industry average, a revenue growth rate of 3.23%, a net margin of 29.38%, an ROE of 9.18%, an ROA of 5.04%, and a low debt-to-equity ratio of 0.25.

Portfolio Pulse from Benzinga Insights

January 18, 2024 | 12:00 pm